Navigation Links
MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
Date:6/28/2008

MOUNTAIN VIEW, Calif., June 28 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today presented data from an in-vitro study evaluating receptor pharmacology of MAP0004, orally inhaled dihydroergotamine (DHE) for the potential treatment of migraine, compared to intravenous (IV) DHE. The study results were among six posters relating to the MAP0004 program that the Company presented at the American Headache Society 50th Annual Scientific Meeting in Boston, MA.

In this receptor pharmacology study, MAP0004 stimulated receptors that relieve migraine at levels comparable to IV DHE, but did not activate receptors associated with side effects frequently seen with IV DHE. In addition, MAP0004 did not affect receptors that have a role in regulating pulmonary function.

"The selective binding of MAP0004 at receptors associated with migraine rather than those associated with side effects offers a mechanistic hypothesis for the favorable safety and efficacy profile of MAP0004 compared to IV DHE that we have observed in our initial clinical studies," said Thomas A. Armer, Ph.D., Chief Scientific Officer of MAP Pharmaceuticals. "The absence of negative effects of MAP0004 on pulmonary function in asthmatic subjects observed in a Phase 2 study is also important because migraine and asthma are frequently co-morbid conditions."

MAP0004 is designed to be self-administered by patients at home via MAP Pharmaceuticals' proprietary Tempo(R) inhaler. In Phase 2 studies with migraneurs and with asthmatics, treatment with MAP0004 was well-tolerated, with no serious adverse events reported. Drug-induced nausea was very low and migraine-associated nausea also decreased with treatment.

The Company presented a poster summariz
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
2. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
3. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
4. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
5. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
6. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
7. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
8. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
9. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
10. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
11. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th edition ... Convention Center from January 21-24. (Logo: ... from top pharmaceutical, fine chemical and specialty chemical companies will ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a ... Leesburg, Virginia is the first in ... chamber. Dr. Susan M. Barnes , Medical ... Barnes and husband, Dr. Cole Taylor , are avid scuba ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... MITI ), a biopharmaceutical company developing novel, ... autoimmune,diseases, announced the start of a phase 1 ... will explore the safety, pharmacokinetics,pharmacodynamics and anti-tumor activity ... MT110 targets the epithelial cell adhesion molecule ...
... an oncolytic product, WOBURN, Mass., April 22 ... treatments for cancer and the prevention,of infectious disease, ... (FDA) has approved the design of a single, ... OncoVEX(GM-CSF) in,previously treated patients with metastatic melanoma. The ...
Cached Medicine Technology:Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 2Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 3Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 4Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 5BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO 2BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO 3
(Date:4/22/2014)... lung cancers are small cell lung cancers (SCLC), ... chemotherapy. However, researchers at Virginia Commonwealth University Massey ... mechanisms leading to this resistance that may lead ... by mediating B-cell lymphoma 2 (Bcl-2) family proteins, ... on their function, this family of proteins can ...
(Date:4/22/2014)... Washington, DC (April 22, 2014) The International ... May 22-26 in Seattle, Washington. The theme of ... life" means in a networked and digital society. ... and attended by over 2,200 Communication scholars representing ... largest scholarly international communication conference in the world. ...
(Date:4/22/2014)... available in German . ... signaling molecules, but their mode of action is complex: ... function and behavior, while at high concentrations they can ... To analyze how redox signaling unfolds in single cells ... has been developed jointly by the teams of LMU ...
(Date:4/22/2014)... the University of Utah (U of U) has successfully ... cases, U of U researchers and their colleagues report ... of Human Genetics . The software, Phevor (Phenotype Driven ... gene mutations by analyzing the exomes, or areas of ... in individual patients and small families. , Sequencing ...
(Date:4/22/2014)... Using nanodot technology, Berkeley Lab researchers have demonstrated ... be used to study the membranes of living ... membrane structures can reveal information critical to whether ... turns cancerous, that can,t be obtained through conventional ... that provide a physical means to both probe ...
Breaking Medicine News(10 mins):Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2Health News:Neuroimaging: Live from inside the cell 2Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 2Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 3Health News:First size-based chromatography technique for the study of livi 2Health News:First size-based chromatography technique for the study of livi 3
... contraceptive Lybrel, which is designed to eliminate monthly menstrual ... contains a lower dose of synthetic hormones in a ... days a year with no placebo pills. The usual ... consecutively, followed by seven placebo pills. ,According ...
... Jefferson Medical College have used gene therapy to reverse ... this gene therapy strategy had "unique and additive ... beta-blockers. ,Reporting in the American Heart Association ... director of the Center for Translational Medicine and the ...
... Researchers at the University of Warwick have found that sexual ... tasks such as navigating with a map in a ... of sexual orientation and withers all mens minds alike just ... worked with the BBC to collect data from over 198,000 ...
... a Californian firm has claimed to have developed super-oxidised ... ,The water, which is made by passing it ... kills bacteria, virus and fungi. ,The company ... aureus (MRSA). ,We would welcome any safe ...
... pregnancy may be exposing their baby to the risk ... study published in the journal Biological sychiatry. ... the mothers womb puts genetically susceptible children at an ... course of study, the researchers studied male and female ...
... called FGFR2 could accelerate the development of new treatments ... at Washington University School of Medicine in St. ... Trust Sanger Institute, which is part of Cambridge University; ... findings in the May 21, 2007, online version of ...
Cached Medicine News:Health News:FDA Approves Wyeth's Oral Contraceptive Lybrel 2Health News:Scientists Use Gene Therapy to Reverse Heart Failure in Animals 2Health News:Scientists Use Gene Therapy to Reverse Heart Failure in Animals 3Health News:Gene Discovery Lays Groundwork for Targeted Therapies for Endometrial Cancer 2Health News:Gene Discovery Lays Groundwork for Targeted Therapies for Endometrial Cancer 3
... has been designed specifically for the ... involved in ward rounds. It is ... dosages, and consultations that are requested ... Registrar during Ward round examinations and ...
... tracking and billing. This ... Handheld application, a complete ... CPT™ and ICD-9-CM codes ... Designed for any medical ...
In addition to the patient data OB-on-Call contains a comprehensive Medications list displaying related drugs by brand name, generic title, and usage description notes....
Archimedes is an innovative specialty calculator. Forget having to remember complicated formulas, just enter the values and out come the results....
Medicine Products: